Umbralisib (Standard)

Overview

Umbralisib (Standard) is the analytical standard of Umbralisib. This product is intended for research and analytical applications. Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Others | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Casein Kinase | Products > Signaling Pathways > Reference Standards

Product Information

• Catalog No.: HY-12279R
• CAS No.: 1532533-67-7
• Molecular Formula: C31H24F3N5O3
• Molecular Weight: 571.55
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source